

To
the Honorable
Mr. Demosthenes Bouros
President of the Pricing Committee
Ministry of Health

Cc.: Mr Marios Salmas, Alternate Minister of Health
Prof. I. Tountas, President of EOF
Mrs M. Skouroliakou, 1st Vice President of EOF
Members of the Pricing Committee

Chalandri, April 26, 2013

Dear Mr Bouros,

The Pricing Committee was convoked in order to meet on Monday 29/4 at 18:30 and discuss on “New Generics”. In view of the said meeting, we would like to inform you that SFEE is completely opposite to the procedure that will be followed for the selective pricing of **only part of the new medicines** (which are pending for almost 2.5 years), which, besides, has no legislative grounds.

According to article 10 par. 3 of the Ministerial Decision ΔΥΓ3(α)/οικ. 7789 (Gov. Gazette 94/A/23.1.2013) “in case a request is filed for the determination of the price of a new medicine, the competent Service issues the relevant Price Bulletin within 90 days from the date the request was filed”. It is further noted that a respective provision is also set out in the Directive (EC) 89/105.

Selective pricing of only a few new medicines is illegal and abusive and has no legislative grounds. On the contrary, it creates a competitive advantage for specific companies, whose products will be priced, and in this manner it favours non-transparency and establishes a distortion in the market by abolishing the principle of equal treatment.

Consequently, dear Mr. President, SFEE pleads that the **relevant legislation is observed and that the Committee abstains from any action that will violate the applicable legal provisions**. Otherwise, pharmaceutical companies reserve the right to claim by all legal means the restoration of justice and the restitution of any damage and loss they will sustain.

Sincerely yours,

Nikos Kefalas
Vice President of SFEE/
Member of the Pricing Committee

Fotis Mangaloussis
Director General